The global chronic wound care market is currently valued at over $13 billion, driven by an urgent clinical need for more effective treatments for diabetic foot ulcers, pressure sores, and hard-to-heal surgical wounds. Despite the massive commercial potential, pharmaceutical pipelines in this space historically face high attrition rates, largely due to poor translational models that fail to accurately predict human clinical outcomes.
Biotts is actively de-risking this development pathway. The company’s latest peer-reviewed study, published in the prestigious journal Frontiers in Pharmacology, delivers the exact scientific and strategic validation that institutional investors and pharmaceutical partners require prior to clinical transition.
By outperforming standard commercial antibiotic therapy in a porcine model, the industry gold standard due to its high structural and functional homology to human skin. The formulation powered by Biotts’ technology establishes a highly predictable foundation for human clinical response. This robust translational data significantly lowers subsequent clinical development risks, providing institutional investors and global pharma partners with the technical validation needed to confidently advance assets into the clinic.
Beyond the immediate therapeutic outcomes, the data confirms the scalability of the proprietary MTC-Y carrier platform, proving its ability to radically enhance the bioavailability of challenging active ingredients without relying on resistance-prone antibiotics. For pharma companies, this creates immediate opportunities for novel intellectual property creation and asset lifecycle management, allowing partners to reformat existing compounds into high-performing topical or transdermal delivery systems.